Sign in
CompletedEarly phase 1

A Clinical Study of Recombinant Oncolytic Adenovirus L-IFN Injection With Multiple Administration Routes in Relapsed/Refractory Solid Tumors

Key facts

Who runs it
Shanghai Fengxian District Central Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Early phase 1
People taking part
25 people enrolled
Started
30 Nov 2021
Ended
31 Dec 2025
Type of study
Interventional
Treatments tested
  • Recombinant L-IFN adenovirus injection
Record updated
16 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Male or female aged ≥ 18 and ≤ 75 years
  • Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard therapy, have no standard therapy, are not eligible for standard therapy at this stage, or have refused standard therapy;
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the length of non-lymph node lesion ≥10 mm or the short diameter of lymph node lesion ≥15 mm according to CT or MRI cross-sectional images;CT scan of the longest axis of measurable lesions ≥10 mm (CT scan thickness ≤5 mm);
  • There were injectable tumor lesions that met the requirements of the current dose group, including superficial lesions and deep lesions that could be injected under the guidance of B-ultrasound /CT;
  • ECOG score of 0 ~ 2
  • Sufficient hematopoietic capacity: ANC ≥1.0 ×10\^9/L (no short-acting albino within 1 week, no long-acting albino within 2 weeks), platelet count ≥75 ×10\^9/L, HGB > 80 g/L (no blood transfusion within 2 weeks);
  • Adequate liver and kidney function: AST and ALT ≤3 times ULN in patients without liver metastasis, ≤5 times ULN in patients with liver metastasis; Total bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-liver origin);Creatinine ≤2.0 ULN and creatinine clearance and creatinine clearance ≥40 mL/min
  • Eligible and fertile patients (male and female) must agree to use a reliable contraceptive method during the trial and for at least 90 days after the last dose; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting treatment
  • PT or INR <1.5 ULN, and APTT <1.5 ULN;
  • Expect to live at least 12 weeks;

Who cannot take part

  • Received any antineoplastic therapy within 2 weeks prior to initial treatment;
  • Subjects requiring systemic corticosteroids (equivalent to >10 mg prednisone/day) within 14 days prior to enrollment or during the study period; The following conditions are allowed to join the group:; Allow subjects to use topical or inhaled corticosteroids; Allows short-term (≤7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases
  • Participated in clinical trials of other drugs or medical devices within 4 weeks
  • Systemic diseases that have not been stably controlled after treatment, such as diabetes, serious organic cardiovascular and cerebrovascular diseases, cardiac insufficiency, hypertension, heart block above ⅱ degree, myocardial infarction within 6 months, cerebral infarction within 6 months, etc
  • Uncontrolled infectious diseases, such as baseline HBV DNA≥2000 IU/ml, anti-HIV positive, HCV-RNA positive
  • Other active infections of significant clinical significance
  • Subjects with other active malignancies within the past 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or breast cancer in situ, that have been completely cured and do not require follow-up treatment are excluded
  • Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granuloma require long-term (more than 2 months) systemic immunosuppressive therapy, but subjects with the following conditions are admitted:; Autoimmune hypothyroidism requiring only hormone replacement therapy; Skin disorders that do not require systemic treatment (e.g., eczema, a rash of less than 10% of the body surface)
  • Subjects with allergic constitution, allergy to immunotherapy or related drugs
  • Organ failure; Coronary heart: grades ⅲ and ⅳ;Or hypertension that cannot be controlled by standard treatment, a history of myocarditis or myocardial infarction within one year; Gallo liver: achieves grade C on the Child-Turcotte-Pugh liver function scale; Gallonic kidney: renal failure and uremia; Lung: symptoms of severe respiratory failure; Brain unconsciously: people with consciousness disorder have active brain metastases
  • Patients with active bleeding and thrombotic diseases requiring treatment
  • Subject suffering from any mental illness, including dementia, altered mental state, that may affect informed consent and understanding of the relevant questionnaire
  • If the investigator determines that they have a serious and uncontrollable disease or other conditions that may affect their acceptance of this study, they are not considered suitable for this study
  • Pregnancy or lactation
  • Patients with uncontrollable pleural and abdominal effusion requiring clinical treatment or intervention

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open-label, dose-escalation study evaluating the safety and tolerability of Recombinant Oncolytic Adenovirus L-IFN Injection (YSCH-01) administered via different routes, including intratumoral injection and aerosol therapy, in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection

The group in the trial

  • Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumorsTreatment being tested

    1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly. If the tumor volume was \>10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time. 2\. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy. 4\. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration,aerosol therapy)

    Treatment: Recombinant L-IFN adenovirus injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study
Publications
Record updated
16 November 2026